NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program, where he discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola. The full press release is available at https://ibn.fm/7XBbY.
NanoViricides is a clinical stage company specializing in creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug being developed for the treatment of RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. Additionally, NanoViricides is developing NV-CoV-2 and NV-CoV-2-R for COVID-19, with the latter encapsulating remdesivir, which is already FDA-approved. The company believes that NV-CoV-2-R could be an approvable drug if safety is comparable to remdesivir.
The initiation of coverage by Noble Capital Markets signals growing interest in NanoViricides' unique nanotechnology platform and its potential to address multiple viral threats. The $6 price target suggests significant upside from current trading levels, reflecting optimism about the company's pipeline and regulatory progress. With FDA Orphan Drug Designation and Rare Pediatric Disease Designation for measles, NanoViricides is positioning itself to tackle both common and neglected viral diseases. The analyst's independent assessment provides investors with a professional evaluation of the company's prospects, which could influence market perception and investment decisions. The coverage also highlights the broader trend of resurgent infectious diseases, making NanoViricides' broad-spectrum approach particularly timely.
For more information about NanoViricides, visit their newsroom at https://ibn.fm/NNVC.
